News

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,

Jointly developed with Microsoft and powered by Azure, Adents Prodigi allows for secure data exchange and helps leverage the power of serialisation data to improve business practices. Cristers

The candidate, known as E2814, is an anti-tau monoclonal antibody set to be tested in human trials for the first time to assess its ability to slow the

The phase II Eagle trial is a randomized, open-label and multi-centre trial designed to assess Imfinzi monotherapy and Imfinzi in combination with anti-CTLA4 antibody tremelimumab against SoC chemotherapy

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs. In 2017, AstraZeneca

The Transaction has been unanimously approved by the Board of Directors of each company. Subject to potential adjustment as described below, based upon an OncoMed net cash balance

The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen. There is a remote possibility that infants, who may be more susceptible

UCB will build a new £150mto £200m research and development facility as part of the total investment over the next five years. The transition to the facility will

Phase III studies PEARL1 and PEARL 2 are planned to include more than 2,000 CSU patients. Charité-Universitätsmedizin Allergie-Centrum-Charité Department of Dermatology and Allergy Dermatology and Allergy Professor and